According to the vesting conditions, it should be the 10th patient into the 2B protocol specifically. This would mean that it is the 10th patient since moving to the 2B protocol in June, so 10 patients in 5-8 months. This also means that the second cohort of the efficacy stage has begun.
Overall a positive sign that there has been an acceleration in recruitment compared to the phase 1 cohorts.
Ann: Quarterly Activity Report & Appendix 4C, page-24
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
0.010(0.69%) |
Mkt cap ! $245.0M | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.50 | $1.43 | $48.84K | 33.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 680 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 340 | 1 |
View Market Depth
| Last trade - 13.37pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
0.010 ( 0.23 %) |
||||
| Open | High | Low | Volume | ||
| $1.44 | $1.49 | $1.43 | 9034 | ||
| Last updated 13.08pm 24/05/2024 ? | |||||
| RAC (ASX) Chart |